title: Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma.
abstract: BACKGROUND
  Inhalation of a single dose of the long-acting beta 2-adrenoceptor agonist salmeterol protects against methacholine-induced airway obstruction and other bronchoconstricting stimuli for at least 12 hours. Hypothetically, twice daily dosing of salmeterol may result in continuous protection.
  
  
  OBJECTIVE
  This study was designed to investigate the protective effect of a single dose of salmeterol and of continuous twice daily treatment on airway responsiveness to methacholine.
  
  
  METHODS
  In a double- blind, parallel study, salmeterol 50 micrograms twice daily was compared with salbutamol 200 micrograms twice daily. Thirty children with mild asthma, who had little or no bronchial obstruction and were hyperresponsive to methacholine (PD20 < or = 150 micro g) were allocated to receive either salmeterol or salbutamol. Airway responsiveness was measured before study entry, 12 hours after a single dose of drug was given, and monthly during 4 months of daily treatment. Measurements were always performed at the same time of the day, 12 hours after the last dose of medication was administered.
  
  
  RESULTS
  No significant differences in FEV 1 were found between treatments at any time point. PD20 significantly increased after the first dose of salmeterol was given (geometric mean, 100 micro g). Geometric mean PD20 values were significantly better during salmeterol treatment than during salbutamol treatment, 52 and 25 micro g, respectively (p = 0.005).
  
  
  CONCLUSIONS
  The protection provided by salmeterol during maintenance treatment was less than that provided after the first dose (p <0.001). However, protection did not diminish during the 4-month treatment period and remained significant compared with baseline (p = 0.003).
authors.affiliation: Department of Pediatrics, Erasmus University, University Hospital, Rotterdam, The Netherlands.
authors.forename: A A
authors.initials: AA
authors.lastname: Verberne
authors.forename: W C
authors.initials: WC
authors.lastname: Hop
authors.forename: F B
authors.initials: FB
authors.lastname: Creyghton
authors.forename: R W
authors.initials: RW
authors.lastname: van Rooij
authors.forename: M
authors.initials: M
authors.lastname: van den Berg
authors.forename: J C
authors.initials: JC
authors.lastname: de Jongste
authors.forename: K F
authors.initials: KF
authors.lastname: Kerrebijn
mesh_terms: D000293:Adolescent; D000403:Airway Resistance / Q000187:drug effects; D000420:Albuterol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001249:Asthma / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology*; D016084:Bronchoconstriction / Q000187:drug effects; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D000068299:Salmeterol Xinafoate
chemical_list: D001993:Bronchodilator Agents; D000068299:Salmeterol Xinafoate; D000420:Albuterol